Regeneron Pharmaceuticals, Inc. $REGN Shares Purchased by Wealth Enhancement Advisory Services LLC

Wealth Enhancement Advisory Services LLC increased its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 82.0% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 17,585 shares of the biopharmaceutical company’s stock after purchasing an additional 7,923 shares during the period. Wealth Enhancement Advisory Services LLC’s holdings in Regeneron Pharmaceuticals were worth $10,256,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of REGN. Salomon & Ludwin LLC purchased a new stake in shares of Regeneron Pharmaceuticals in the 3rd quarter valued at approximately $27,000. Migdal Insurance & Financial Holdings Ltd. acquired a new position in Regeneron Pharmaceuticals in the second quarter valued at approximately $31,000. Traub Capital Management LLC purchased a new position in Regeneron Pharmaceuticals in the second quarter worth approximately $38,000. Berbice Capital Management LLC increased its stake in Regeneron Pharmaceuticals by 300.0% during the second quarter. Berbice Capital Management LLC now owns 80 shares of the biopharmaceutical company’s stock worth $42,000 after acquiring an additional 60 shares during the last quarter. Finally, E Fund Management Hong Kong Co. Ltd. raised its position in Regeneron Pharmaceuticals by 87.5% in the third quarter. E Fund Management Hong Kong Co. Ltd. now owns 75 shares of the biopharmaceutical company’s stock valued at $42,000 after purchasing an additional 35 shares during the period. 83.31% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Regeneron Pharmaceuticals news, Director Christine A. Poon sold 6,500 shares of the stock in a transaction dated Wednesday, October 29th. The stock was sold at an average price of $654.27, for a total value of $4,252,755.00. Following the sale, the director owned 2,352 shares of the company’s stock, valued at $1,538,843.04. This trade represents a 73.43% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, VP Jason Pitofsky sold 431 shares of Regeneron Pharmaceuticals stock in a transaction dated Friday, November 7th. The shares were sold at an average price of $651.43, for a total value of $280,766.33. Following the completion of the transaction, the vice president owned 4,233 shares of the company’s stock, valued at $2,757,503.19. The trade was a 9.24% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 8,431 shares of company stock worth $5,733,521 in the last quarter. 7.02% of the stock is owned by company insiders.

Key Regeneron Pharmaceuticals News

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Seeking Alpha previews Regeneron’s Q4 and expects an earnings beat and a strong 2026, maintaining a Buy rating and noting the shares have rallied >16% since the author’s prior note — this supports upside if results meet or exceed guidance. Read More.
• Positive Sentiment: Zacks says Regeneron has the right setup to beat upcoming earnings (Earnings “ESP”/estimates upside), which could trigger further upside if the company reports above-consensus results. Read More.
• Positive Sentiment: Evercore ISI raised its price target on REGN from $750 to $875 and kept an “outperform” call — a material analyst upgrade that increases implied upside and can support buying interest. Read More.
• Positive Sentiment: MarketBeat aggregation (reported on DefenseWorld/American Banking News) shows an average analyst rating of “Moderate Buy” across ~28 brokerages, indicating broad analyst conviction that could limit downside absent a negative print. Read More.
• Neutral Sentiment: Reminders that Regeneron will release quarterly earnings on Friday — serves as the immediate event risk/reward driver; expect heightened volume and larger intraday moves around the report. Read More.
• Neutral Sentiment: Zacks compares REGN with Illumina (ILMN) on valuation — useful context for investors weighing sector alternatives, but not an immediate catalyst for REGN alone. Read More.
• Neutral Sentiment: A Zacks piece highlights two medical names that could beat earnings (including REGN), which reinforces market attention on earnings-season upside but is not new company-specific data. Read More.

Analysts Set New Price Targets

A number of research firms have recently weighed in on REGN. Guggenheim increased their price target on Regeneron Pharmaceuticals from $815.00 to $865.00 and gave the stock a “buy” rating in a report on Wednesday, October 29th. Scotiabank increased their target price on shares of Regeneron Pharmaceuticals from $650.00 to $770.00 and gave the stock a “sector perform” rating in a research note on Monday, November 24th. Zacks Research upgraded shares of Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Thursday, January 8th. Canaccord Genuity Group upped their price objective on shares of Regeneron Pharmaceuticals from $850.00 to $1,057.00 and gave the stock a “buy” rating in a report on Thursday, December 4th. Finally, Citigroup increased their price objective on shares of Regeneron Pharmaceuticals from $660.00 to $700.00 and gave the stock a “buy” rating in a research report on Wednesday, October 29th. Three analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and eight have given a Hold rating to the company. Based on data from MarketBeat, Regeneron Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus target price of $794.70.

Regeneron Pharmaceuticals Trading Down 0.3%

Shares of REGN stock opened at $753.55 on Friday. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $476.49 and a fifty-two week high of $821.11. The company has a 50 day moving average price of $755.38 and a 200 day moving average price of $643.06. The stock has a market capitalization of $79.20 billion, a P/E ratio of 18.04, a price-to-earnings-growth ratio of 1.97 and a beta of 0.39. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.33 and a current ratio of 4.06.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Tuesday, October 28th. The biopharmaceutical company reported $11.83 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $9.73 by $2.10. The company had revenue of $3.75 billion for the quarter, compared to analyst estimates of $3.57 billion. Regeneron Pharmaceuticals had a net margin of 32.13% and a return on equity of 13.76%. The firm’s quarterly revenue was up .9% on a year-over-year basis. During the same period in the prior year, the business earned $12.46 EPS. Equities research analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, December 5th. Investors of record on Thursday, November 20th were paid a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a yield of 0.5%. The ex-dividend date of this dividend was Thursday, November 20th. Regeneron Pharmaceuticals’s payout ratio is presently 8.43%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.